RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?

Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib

(2018) Francesco Tovoli et al.   EUROPEAN RADIOLOGY

Observer variability in RECIST-based tumour burden measurements: a meta-analysis

(2016) Soon Ho Yoon et al.   EUROPEAN JOURNAL OF CANCER

Target Lesion Selection

(2014) Sebastian Keil et al.   INVESTIGATIVE RADIOLOGY

Observer variability in a phase II trial – assessing consistency in RECIST application

(2012) Kristin Skougaard et al.   ACTA ONCOLOGICA

Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1

(2012) Daniela Muenzel et al.   Radiology and Oncology

The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST)

(2009) M H S E DARKEH et al.   BRITISH JOURNAL OF RADIOLOGY

Validation of novel imaging methodologies for use as cancer clinical trial end-points

(2008) D.J. Sargent et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of lymph nodes with RECIST 1.1

(2008) L.H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER